GlassScriptPhysician profile
Geraldine Dolan
NPI 1942643424
$1,478.99
in general payments reported to CMS, 2019-2025
24 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $330 · 2023: $242 · 2024: $265 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $203.88 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $183.70 | 2021-2024 | Velphoro |
| Amgen INC. | $155.68 | 2021-2024 | Tavneos |
| Ardelyx, INC. | $110.97 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $108.61 | 2021-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $92.72 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.33 | 2021-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $81.39 | 2022-2024 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.84 | 2022-2025 | Xifaxan, Trulance |
| Aurinia Pharma U.S., INC. | $68.36 | 2022-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $42.53 | 2021-2022 | |
| Akebia Therapeutics INC | $32.45 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $32.19 | 2024-2025 | Jynarque |
| Daiichi Sankyo INC. | $31.32 | 2021-2022 | |
| Abbott Laboratories | $25.37 | 2025 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.33 | 2025 | Cologuard Collection Kit |
| Scpharmaceuticals INC. | $20.82 | 2025 | |
| Fresenius USA Manufacturing, INC. | $15.04 | 2023 | Velphoro, Korsuva |
| Lilly USA, LLC | $15.00 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $14.99 | 2022 | |
| Novo Nordisk INC | $14.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.64 | 2023 | Lokelma |
| Merck Sharp & Dohme LLC | $14.42 | 2021 | |
| Abbvie INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldine Dolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.